SCHEMBL6188317

SCHEMBL6188317

CC(C)(C)ONC(=O)c1cccc(C#N)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.51
GSK3B P49841 2/20 0.48
GAA P10253 1/20 0.46
GPR139 Q6DWJ6 1/20 0.45
S1PR3 Q99500 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.45
VNN1 O95497 1/20 0.44
KAT6A Q92794 1/20 0.44
ALDH1A1 P00352 1/20 0.44
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
ABCC9 O60706 1/20 0.43
ABCC8 Q09428 1/20 0.43
KCNJ11 Q14654 1/20 0.43
KCNJ8 Q15842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13527479 0.83 GRM5 (0.55) GRM5GSK3BGAAGPR139S1PR3
SCHEMBL13701651 0.80 ANO1 (0.58) GRM5GSK3BGPR139IRAK4VNN1
SCHEMBL549058 0.78 KDM4E (0.59) GAAALDH1A1
SCHEMBL6647997 0.78 ALDH1A1 (0.51) KAT6AALDH1A1
SCHEMBL549057 0.78 HDAC8 (0.42) ALDH1A1
SCHEMBL1544890 0.78 GSK3B (0.60) GRM5GSK3BGAAGPR139S1PR3
SCHEMBL31019130 0.78 GSK3B (0.60) GRM5GSK3BGAAGPR139S1PR3
SCHEMBL3819152 0.78 GRM5 (0.58) GRM5GSK3BGAAGPR139S1PR3
SCHEMBL3610584 0.77 KAT6A (0.59) GRM5GSK3BGPR139S1PR3IRAK4
SCHEMBL12251421 0.77 GPR139 (0.57) GRM5GSK3BGAAGPR139S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181283-B1 DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES AGOURON PHARMA (US) 2005-02-02 EP disclosed
US-6620828-B2 Antiproliferative agents AGOURON PHARMACEUTICALS, INC. 2003-09-16 US disclosed
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-02-28 US disclosed
EP-1181283-A1 DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-02-27 EP disclosed
WO-2000075120-A1 DIAMINOTHIAZOLES AND THEIR USE FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025976-A1 Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use BRAF, CDK2, CHUK GRM5 2250/4885GSK3B 270/4885GAA 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.